Aapkes, Sophie E. http://orcid.org/0000-0002-2037-1832
de Haas, Robbert J.
Bernts, Lucas H. P.
Blijdorp, Charles J.
Dekker, Sosha E. I.
van Gastel, Maatje D. A.
Meijer, Esther
Veldman, Abigail
Drenth, Joost P. H.
Gansevoort, Ron T.
,
Drenth, J. P. H.
de Fijter, J. W.
Gansevoort, R. T.
Meijer, E.
Peters, D. J. M.
Visser, F. W.
Wetzels, J. F. M.
Zietse, R.
Funding for this research was provided by:
Ipsen Biopharmaceuticals
Rijksinstituut voor Volksgezondheid en Milieu (LSHM15018)
Nierstichting (CP10.12, CP15.01)
Article History
Accepted: 10 March 2021
First Online: 29 March 2021
Declarations
:
: Ron T. Gansevoort received grant support and fees from Galapagos, IPSEN, Otsuka Pharmaceuticals, and Sanofi-Genzyme for serving on advisory boards and steering committees. He also holds the Orphan Medicinal Product Designation status at the European Medicines Agency for lanreotide as treatment for ADPKD (EMA/OD/027/15). Joost P.H. Drenth has received grant support and fees from IPSEN and Novartis for serving on advisory boards and consultancy. Esther Meijer has received consultancy fees from Otuska. All money is paid to their respective institutions. Sophie E. Aapkes, Robbert J. de Haas, Lucas H.P. Bernts, Charles J. Blijdorp, Sosha E.I. Dekker, Maatje D.A. van Gastel, and Abigail Veldman have no other potential conflicts of interest relevant to this article to report.
: The design, methods, and results of the original DIPAK 1 trial have been published previously. The Institutional Review Board at each of the participating hospitals approved the protocol and all patients provided written informed consent. The study was registered at ClinicalTrials.gov (NCT01616927).
: All patients provided written informed consent for this study.
: All patients provided written informed consent for publication.
: De-identified individual participant data collected during the trial will be made available upon request to researchers who provide a methodologically sound proposal and whose use of the data has been approved by the DIPAK Steering Committee.
: Not applicable.
: All authors contributed to data collection and interpretation. SA and AV scored the MR images for the primary outcome, and, in case of doubt or inconsistency, RdH made the final decision. SA wrote the first draft of the manuscript. LB, CB and SD contributed to the collection of follow-up data after the formal end of the trial. All authors contributed to and approved the final manuscript.